MedDataX Logo

The Role of Endogenous GLP-1 (Glycolipoprotein) in Regulating Glucose Stimulated Brain Activity

NCT ID: NCT01918566

Last Updated: 2013-08-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-03-31

Study Completion Date

2013-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Our objective is to investigate neuro-anatomical correlates of the regulation of energy intake by means of functional MRI. Administration of glucose with and without lactisole and exendin as well as fructose is followed by functional brain MRI, and findings are correlated with serum GLP-1 levels as an endogenous satiety signal in humans.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Exploratory Behavior

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

300ml tap water

Single intragastric instillation of 300ml tap water via nasogastric tube

Group Type PLACEBO_COMPARATOR

tap water

Intervention Type DIETARY_SUPPLEMENT

Glucose

Single intragastric instillation of 75g Glucose in 300ml tap water via nasogastric tube

Group Type ACTIVE_COMPARATOR

Single intragastric instillation of 75g Glucose in 300ml tap water via nasogastric tube

Intervention Type DIETARY_SUPPLEMENT

Glucose plus Lactisole

Single intragastric instillation of 75g Glucose in 300ml tap water with 450ppm lactisole

Group Type ACTIVE_COMPARATOR

Single intragastric instillation of 75g Glucose in 300ml tap water with 450ppm lactisole

Intervention Type DIETARY_SUPPLEMENT

Fructose

Single intragastric instillation of 25g Fructose in 300ml tap water via nasogastric tube

Group Type ACTIVE_COMPARATOR

25g Fructose in 300ml tap water

Intervention Type DIETARY_SUPPLEMENT

Glucose and Exendin

Single intragastric instillation of 75g glucose in 300ml tap water with 600pmol/kg/min exendin 9-39

Group Type ACTIVE_COMPARATOR

75g glucose in 300ml tap water with 600pmol/kg/min exendin 9-39

Intervention Type DIETARY_SUPPLEMENT

tap water, lactisole

Single intragastric instillation of 300ml tap water with 450ppm lactisole

Group Type SHAM_COMPARATOR

300ml tap water with 450ppm lactisole

Intervention Type DIETARY_SUPPLEMENT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

tap water

Intervention Type DIETARY_SUPPLEMENT

Single intragastric instillation of 75g Glucose in 300ml tap water via nasogastric tube

Intervention Type DIETARY_SUPPLEMENT

Single intragastric instillation of 75g Glucose in 300ml tap water with 450ppm lactisole

Intervention Type DIETARY_SUPPLEMENT

25g Fructose in 300ml tap water

Intervention Type DIETARY_SUPPLEMENT

75g glucose in 300ml tap water with 600pmol/kg/min exendin 9-39

Intervention Type DIETARY_SUPPLEMENT

300ml tap water with 450ppm lactisole

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* right-handed healthy males, no drugs, non-smoking

Exclusion Criteria

* drug abuse, smoker, left-handed, claustrophobia
Minimum Eligible Age

18 Years

Maximum Eligible Age

35 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Basel, Switzerland

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Christoph Beglinger, MD

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Basel, Switzerland

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospital

Basel, , Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

EKBB 298/12

Identifier Type: -

Identifier Source: org_study_id